CN Mobile Logo


Hematologic Malignancies

Melanoma Risk Increased in CLL/SLL Patients

Results of a new study have indicated that the risk of developing melanoma may be almost doubled among survivors of chronic lymphocytic leukemia/small lymphocytic lymphoma who were treated with certain chemotherapeutic agents or who had specific immune-related medical conditions.

Hematologic Malignancies

Adding elotuzumab to lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma appears to result in better efficacy and safety.

A case study of a 15-year-old CML patient suggests that a reduced intensity conditioning regimen following hematopoietic stem cell transplantation could be a good treatment option for young CML patients. The patient went on to have two pregnancies with no neonatal complications.

The FDA approved the proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone, to be used as a second-line treatment in multiple myeloma.

PEG-asparaginase had both similar safety and efficacy to intramuscular native E coli l-asparaginase for the treatment of children with ALL in complete remission.

An increased risk for coronary heart disease was found with increasing mean heart dose of radiation in survivors of Hodgkin lymphoma.

Results from the phase II SORAML trial indicated that adding sorafenib to standard chemotherapy for younger patients with acute myeloid leukemia was effective, but also resulted in increased toxicity.

Many chronic myeloid leukemia patients who discontinue second-line dasatinib maintain a deep molecular response, according to a new study.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.